checkAd

     196  0 Kommentare Orion Corporation's financial reporting and Annual General Meeting in 2019

    ORION CORPORATION          STOCK EXCHANGE RELEASE           18 JULY 2018 at 11.00 EEST             
             

    Orion Corporation's financial reporting and Annual General Meeting in 2019 
     

    Orion Corporation will publish its Financial Statement Release 2018 on Wednesday, 6 February 2019.
    The publication dates of the Interim Reports and the Half-Year Financial Report in 2019 are as follows:

    Interim Report January-March 2019 
    Half-Year Financial Report January-June 2019
    Interim Report January-September 2019
      Thursday, 25 April 2019
    Wednesday, 17 July 2019
    Wednesday, 23 October 2019

    The Financial Statements and the Report of the Board of Directors for 2018 will be published on the Company's website at the latest in week 10/2019.

    The Annual General Meeting is planned to be held on Tuesday, 26 March 2019 in Helsinki.

    Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases. 

    Orion Corporation

    Timo Lappalainen
    President and CEO
      Olli Huotari
    SVP, Corporate Functions
     

                                                                                                                                       
    Contact person:
    Lilli Riikonen, Communications Manager
    tel. +358 50 966 2319

    Publisher:
    Orion Corporation
    Communications
    Orionintie 1A, FI-02200 Espoo, Finland
    Homepage: www.orion.fi

    Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2017 amounted to EUR 1,034 million and the company had about 3,200 employees. Orion's A and B shares are listed on Nasdaq Helsinki.




    This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Orion Oyj via Globenewswire




    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Orion Corporation's financial reporting and Annual General Meeting in 2019 ORION CORPORATION          STOCK EXCHANGE RELEASE           18 JULY 2018 at 11.00 EEST                       Orion Corporation's financial reporting and Annual General Meeting in 2019    Orion Corporation …

    Schreibe Deinen Kommentar

    Disclaimer